Baxter International (NYSE: BAX) — Perfil da empresa, notícias e dados financeiros
Baxter International specializes in healthcare products for critical therapies, focusing on kidney health and immune disorders globally.
Baxter International
Baxter International is a global medical technology company that develops, manufactures, and markets a broad portfolio of healthcare products, medical devices, and pharmaceutical therapies. Its operations encompass clinical nutrition, intravenous solutions, infusion systems, surgical sealants, patient monitoring equipment, smart hospital beds, and diagnostic tools used in hospitals, primary care facilities, and home care environments. Following the divestiture of its kidney care business, the company focuses on advancing patient care, streamlining clinical workflows, and supporting critical care delivery across hospital networks and healthcare providers globally.
Resumo
Operações
Produtos e/ou serviços de Baxter International
- Medical Products & Therapies: Manages intravenous solutions, administration sets, infusion pumps, vascular access devices, and parenteral nutrition products used across hospital, clinical, and alternate site care settings to deliver essential fluids and medications.
- Healthcare Systems & Technologies: Manufactures smart hospital beds, patient room technology, clinical workflow communication systems, and patient monitoring systems designed to optimize care team efficiency and improve patient outcomes in acute care environments.
- Advanced Surgery: Produces surgical sealants, total hemostatic agents, tissue adhesives, and biosurgery products utilized by surgical teams during operations to control bleeding, prevent tissue adhesion, and improve surgical recovery.
- Pharmaceuticals: Supplies ready-to-use injectable medications, inhaled anesthesia agents, generic injectable pharmaceuticals, and specialized pharmacy compounding services for hospital critical care, surgical suites, and specialized clinical departments globally.
- Front Line Care: Offers vital signs monitoring equipment, physical assessment diagnostic tools, cardiology screening devices, and respiratory care products used by primary care physicians, emergency care providers, and health system outpatient centers.
- Clinical Nutrition: Delivers specialized parenteral nutrition formulations, lipid emulsions, amino acid infusions, and automated compounding technologies designed to provide essential nutrient support to critical care and chronically ill patients.
equipe executiva do Baxter International
- Andrew P. HiderCEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director
- David S. RosenbloomExecutive VP & General Counsel
- Maria SorianoGroup President of Infusion Therapies & Platforms
- John Terence RogersExecutive VP & CFO
- Bernie HeineInterim Chief Accounting Officer & Controller
- Charles PatelSenior VP & Chief Information Officer
- Kevin MoranVice President & Head of Investor Relations
- Stacey EisenSVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation
- Cynthia CarlisleExecutive VP & Chief Human Resources Officer
- James W. BorziExecutive VP & Chief Supply Chain Officer
Histórico de dividendos
Dividendos por ação pagos pela Baxter International, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $0.0300 |
| FY2025 | — | — | — | $0.5200 |
| FY2024 | — | — | — | $1.0400 |
| FY2023 | — | — | — | $1.1600 |
| FY2022 | — | — | — | $1.1500 |
Principais indicadores financeiros
Resultados divulgados pela Baxter International, em USD.
- Cap. de mercado
- 12,9 bi
- Receita (TTM)
- 11,5 bi
- P/L
- —
- LPA (diluído, TTM)
- -1.9
- Dividend yield
- 0.8%
- Margem de lucro
- -9.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 11,2 bi | -308 mi | -957 mi | |
| 10,6 bi | 14 mi | -649 mi | |
| 10,4 bi | 707 mi | 2,7 bi | |
| 10,1 bi | -2,8 bi | -2,4 bi |